Edelman taps Winkler to head corporate health

Share this article:
Edelman named Shellie Winkler EVP, corporate health in the Eastern region. With 14 years of experience in healthcare PR, Winkler joins from Ogilvy, where she was director of the corporate practice and developed expertise in women’s health, cardiovascular and neuroscience.

Winkler will work out of the New York office, reporting to Matt Harrington, president, Eastern Region and collaborating with Nancy Turett, global president for health. She will serve on the leadership teams for Edelman’s Health Sector and Corporate & Public Affairs practices. The company’s Corporate Affairs practice helps clients navigate critical junctures like mergers and acquisitions, stock listings, corporate brand relaunches and shifts in business, product and operations strategy.

Edelman, she said, “has more leverageable assets in its Corporate Affairs and Health practices that, when brought together, can really make a differentiated, first-in-class offering for clients.”
Its healthcare practices include Rx Health, Consumer Health, Health Policy and Public Affairs, Health Branding, Life Sciences, Health Media, Health Alliances and BioScience Communications.

Share this article:
You must be a registered member of MMM to post a comment.

Next Article in Channel

Email Newsletters

MM&M Future Leaders

Register now

Early bird $1,950 before 31 October 2014

*Group discounts available on request 


Patient access to pharmaceuticals is a tale of two worlds—affordability has improved for the majority, while the minority is hampered by cost, distribution and red tape. To provide marketers with a well-rounded perspective, MM&M presents this e-book chock full of key insights. Click here to access it.

More in Channel

Five things for pharma marketers to know: Monday, September 15

Five things for pharma marketers to know: ...

Pharma has sought 76 meetings with FDA over biosimilars; Gilead licenses Sovaldi to India generic drugmakers; Pfizer and Ranbaxy Lipitor lawsuit dismissed.

Liraglutide, aiming for new indication, gets new name

Liraglutide, aiming for new indication, gets new name

Why Novo Nordisk is choosing not to leverage Victoza's brand equity as it seeks a weight-loss indication for liraglutide.

Five things for pharma marketers to know: Friday, September 12

Five things for pharma marketers to know: Friday, ...

An FDA panel voted in favor of liraglutide for weight loss; Allergan investors backing an attempted takeover of the firm crossed a critical threshold; and 100 million health wearables are ...